# Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

> **NCT07102979** · NA · ENROLLING_BY_INVITATION · sponsor: **Chang Gung Memorial Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Ursodeoxycholic Acid (URSO)
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT07102979
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102979, "Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07102979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*